- Home
- RNAZ vs HSDT Comparison
RNAZ vs HSDT Comparison
Compare RNAZ & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- HSDT
- Stock Information
- Founded
- RNAZ 2016
- HSDT N/A
- Country
- RNAZ United States
- HSDT United States
- Employees
- RNAZ N/A
- HSDT N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RNAZ Health Care
- HSDT Health Care
- Exchange
- RNAZ Nasdaq
- HSDT Nasdaq
- Market Cap
- RNAZ 6.1M
- HSDT 6.4M
- IPO Year
- RNAZ 2021
- HSDT N/A
- Fundamental
- Price
- RNAZ $11.36
- HSDT $22.75
- Analyst Decision
- RNAZ Strong Buy
- HSDT Hold
- Analyst Count
- RNAZ 1
- HSDT 1
- Target Price
- RNAZ $280.00
- HSDT N/A
- AVG Volume (30 Days)
- RNAZ 10.7K
- HSDT 1.2M
- Earning Date
- RNAZ 11-13-2025
- HSDT 11-11-2025
- Dividend Yield
- RNAZ N/A
- HSDT N/A
- EPS Growth
- RNAZ N/A
- HSDT N/A
- EPS
- RNAZ N/A
- HSDT N/A
- Revenue
- RNAZ N/A
- HSDT $295,000.00
- Revenue This Year
- RNAZ N/A
- HSDT N/A
- Revenue Next Year
- RNAZ N/A
- HSDT $75.13
- P/E Ratio
- RNAZ N/A
- HSDT N/A
- Revenue Growth
- RNAZ N/A
- HSDT N/A
- 52 Week Low
- RNAZ $6.15
- HSDT $5.37
- 52 Week High
- RNAZ $739.20
- HSDT $1,200.00
- Technical
- Relative Strength Index (RSI)
- RNAZ 56.35
- HSDT 86.15
- Support Level
- RNAZ $10.67
- HSDT $5.78
- Resistance Level
- RNAZ $11.45
- HSDT $24.49
- Average True Range (ATR)
- RNAZ 0.61
- HSDT 1.62
- MACD
- RNAZ 0.10
- HSDT 2.35
- Stochastic Oscillator
- RNAZ 83.81
- HSDT 90.70
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.